Technical Analysis for MLNT - Melinta Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 3.75 -5.06% -0.20
MLNT closed down 5.06 percent on Wednesday, July 17, 2019, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Aug 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MLNT trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish -5.06%
1,2,3 Pullback Bullish Bullish Swing Setup -5.06%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.06%

Older signals for MLNT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.
Medical Specialties Pharmaceutical Infectious Diseases Antibiotics Microbiology Healthcare Associated Infections Bacterial Diseases Pathogenic Bacteria Staphylococcus Aureus Community Acquired Bacterial Pneumonia
Is MLNT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 31.45
52 Week Low 1.62
Average Volume 3,169,128
200-Day Moving Average 7.3142
50-Day Moving Average 3.8948
20-Day Moving Average 5.668
10-Day Moving Average 5.302
Average True Range 0.8095
ADX 37.24
+DI 33.4331
-DI 26.2317
Chandelier Exit (Long, 3 ATRs ) 6.1715
Chandelier Exit (Short, 3 ATRs ) 4.1285
Upper Bollinger Band 7.8807
Lower Bollinger Band 3.4553
Percent B (%b) 0.07
BandWidth 78.076923
MACD Line 0.1138
MACD Signal Line 0.4972
MACD Histogram -0.3835
Fundamentals Value
Market Cap 196.91 Million
Num Shares 52.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -1.99
Price-to-Sales 6.92
Price-to-Book 0.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.22
Resistance 3 (R3) 4.24 4.10 4.14
Resistance 2 (R2) 4.10 3.98 4.09 4.11
Resistance 1 (R1) 3.93 3.91 3.86 3.91 4.09
Pivot Point 3.79 3.79 3.76 3.78 3.79
Support 1 (S1) 3.62 3.67 3.55 3.60 3.41
Support 2 (S2) 3.48 3.60 3.47 3.39
Support 3 (S3) 3.31 3.48 3.36
Support 4 (S4) 3.29